Management of complicated infections in the era of antimicrobial resistance: The role of tigecycline

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 7, 2009, Pages 1213-1222

  Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

Antibiotic; Antimicrobial resistance; Clinical utility; Complicated infections; Ease of use; Tigecycline

Indexed keywords

AMIKACIN; AZTREONAM; CEFEPIME; CEFTOBIPROLE; CILASTATIN PLUS IMIPENEM; DALBAVANCIN; DAPTOMYCIN; DORIPENEM; GENTAMICIN; IMIPENEM; LINEZOLID; MEROPENEM; MINOCYCLINE; PIPERACILLIN PLUS TAZOBACTAM; TEICOPLANIN; TIGECYCLINE; VANCOMYCIN; WARFARIN; ANTIINFECTIVE AGENT; DRUG DERIVATIVE;

ABDOMINAL INFECTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; CLINICAL TRIAL; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG COST; DRUG EFFICACY; DRUG SAFETY; EXFOLIATIVE DERMATITIS; FEVER; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; HYPOTENSION; INFECTION COMPLICATION; INJECTION SITE REACTION; MEDLINE; MULTIDRUG RESISTANCE; MUSCLE DISEASE; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OTOTOXICITY; PROTEUS; PSEUDOMEMBRANOUS COLITIS; PSEUDOMONAS AERUGINOSA; RASH; REVIEW; SEIZURE; SKIN INFECTION; SKIN MANIFESTATION; TASTE DISORDER; THROMBOPHLEBITIS; THRUSH; URTICARIA; VOMITING; BACTERIAL INFECTION; COST BENEFIT ANALYSIS; DRUG INTERACTION; ECONOMICS;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; COST-BENEFIT ANALYSIS; DRUG INTERACTIONS; DRUG RESISTANCE, BACTERIAL; HUMANS; MINOCYCLINE;

EID: 67649522455     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560902900853     Document Type: Review

References (110)

1. Ellis-Grosse EJ, Babinchak T, Dartois N, et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005;41(Suppl 5):S341-53 • Reports pivotal Phase III trial results for tigecycline. (Pubitemid 41170381)
2. Sacchidanand S, Penn RL, Embil JM, et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from a phase 3, randomized, double-blind trial. Int J Infect Dis 2005;9:251-261 (Pubitemid 41196869)
3. Babinchak T, Ellis-Grosse E, Dartois N, et al. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005;41(Suppl 5):S354-67 • Reports pivotal Phase III trial results for tigecycline. (Pubitemid 41170382)
4. Oliva ME, Rekha A, Yellin A, et al. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744]. BMC Infect Dis 2005;5:88
5. Tanaseanu C, Bergallo C, Teglia O, et al. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn Microbiol Infect Dis 2008;61:329-338 (Pubitemid 351858575)
6. Muralidharan G, Micalizzi M, Speth J, et al. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005;49:220-229 (Pubitemid 40065796)
7. Ji AJ, Saunders JP, Amorusi P, et al. A sensitive human bone assay for quantitation of tigecycline using LC/MS/MS. J Pharm Biomed Anal 2008;48:866-875
8. Conte JE Jr, Golden JA, Kelly MG, Zurlinden E. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int J Antimicrob Agents 2005;25:523-529 (Pubitemid 40732607)
9. Cunha BA. Once-daily tigecycline therapy of multidrug-resistant and non-multidrug-resistant gram-negative bacteremias. J Chemother 2007;19:232-233 (Pubitemid 46697747)
10. Rodvold KA, Gotfried MH, Cwik M, et al. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother 2006;58:1221-1229 (Pubitemid 44884142)
11. Scheetz MH, Reddy P, Nicolau DP, et al. Peritoneal fluid penetration of tigecycline. Ann Pharmacother 2006;40:2064-2067 (Pubitemid 44747481)
12. Sun HK, Ong CT, Umer A, et al. Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations. Antimicrob Agents Chemother 2005;49:1629-1632 (Pubitemid 40463407)
13. Ong CT, Babalola CP, Nightingale CH, Nicolau DP. Penetration, efflux and intracellular activity of tigecycline in human polymorphonuclear neutrophils (PMNs). J Antimicrob Chemother 2005;56:498-501 (Pubitemid 41264126)
14. MacGowan AP. Tigecycline pharmacokinetic/pharmacodynamic update. J Antimicrob Chemother 2008;62(Suppl 1):i11-6
15. Curcio D, Fernandez F, Duret F. Tigecycline use in critically ill older patients: case reports and critical analysis. J Am Geriatr Soc 2007;55:312-313 (Pubitemid 46184415)
16. Muralidharan G, Fruncillo RJ, Micalizzi M, et al. Effects of age and sex on single-dose pharmacokinetics of tigecycline in healthy subjects. Antimicrob Agents Chemother 2005;49:1656-1659 (Pubitemid 40463415)
17. Hoffmann M, Demaio W, Jordan RA, et al. Metabolism, excretion and pharmacokinetics of [14C]tigecycline, a first-in-class glycylcycline antibiotic, after intravenous infusion to healthy male subjects. Drug Metab Dispos 2007;35:1543-1553 (Pubitemid 47296047)
18. Eagye KJ, Kuti JL, Dowzicky M, Nicolau DP. Empiric therapy for secondary peritonitis: a pharmacodynamic analysis of cefepime, ceftazidime, ceftriaxone, imipenem, levofloxacin, piperacillin/tazobactam, and tigecycline using Monte Carlo simulation. Clin Ther 2007;29:889-899 (Pubitemid 47223435)
19. Breedt J, Teras J, Gardovskis J, et al. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother 2005;49:4658-4666 (Pubitemid 41552597)
20. Grolman DC. Therapeutic applications of tigecycline in the management of complicated skin and skin structure infections. Int J Infect Dis 2007;11(Suppl 1):S7-15 (Pubitemid 46977799)
21. Nordberg P, Monnet DL, Cars O. Antibacterial drug resistance: options for concerted action. WHO department of medicines policy and standards; 2005 • Comprehensive assessment of the in vitro potency of tigecycline and comparator agents against anaerobic bacteria.
22. Taccone FS, Rodriguez-Villalobos H, De Backer D, et al. Successful treatment of septic shock due to pan-resistant Acinetobacter baumannii using combined antimicrobial therapy including tigecycline. Eur J Clin Microbiol Infect Dis 2006;25:257-260 (Pubitemid 43800546)
23. Petersen PJ, Labthavikul P, Jones CH, Bradford PA. In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis. J Antimicrob Chemother 2006;57(3):573-576
24. Mercier RC, Kennedy C, Meadows C. Antimicrobial activity of tigecycline (GAR-936) against Enterococcus faecium and Staphylococcus aureus used alone and in combination. Pharmacotherapy 2002;22:1517-1523 (Pubitemid 35429946)
25. Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. Pharmacokinetic/ pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent. Diagn Microbiol Infect Dis 2005;52:165-171 • Reviews the pharmacokinetic and pharmacodynamic profiles of tigecycline. (Pubitemid 41133541)
26. Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin Infect Dis 2005;41(Suppl 5):S333-40 (Pubitemid 41170380)
27. Meagher AK, Passarell JA, Cirincione BB, et al. Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections. Antimicrob Agents Chemother 2007;51:1939-1945 • Explores and reports the pharmacodynamic profile of tigecycline in patients undergoing treatment with complicated skin and skin-structure infections. (Pubitemid 46903077)
28. Van Wart SA, Cirincione BB, Ludwig EA, et al. Population pharmacokinetics of tigecycline in healthy volunteers. J Clin Pharmacol 2007;47:727-737 (Pubitemid 46800414)
29. Van Wart SA, Owen JS, Ludwig EA, et al. Population pharmacokinetics of tigecycline in patients with complicated intra-abdominal or skin and skin structure infections. Antimicrob Agents Chemother 2006;50:3701-3707 (Pubitemid 44684884)
30. Troy SM, Muralidharan G, Micalizzi M. The effects of renal disease on the pharmacokinetics of tigecycline (GAR-936) [abstract A-43]. Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago) Washington, DC: American Society for Microbiology 2003:5
31. Munoz-Price LS, Lolans K, Quinn JP. Four cases of invasive methicillin-resistant Staphylococcus aureus (MRSA) infections treated with tigecycline. Scand J Infect Dis 2006;38:1081-1084 (Pubitemid 44869284)
32. Wyeth Pharmaceuticals I. TYGACIL® (TIGECYCLINE) FOR INJECTION prescribing information W10521C002 ET01. 2006(Rev 06/07)
33. Saner FH, Heuer M, Rath PM, et al. Successful salvage therapy with tigecycline after linezolid failure in a liver transplant recipient with MRSA pneumonia. Liver Transpl 2006;12:1689-1692 (Pubitemid 44742550)
34. Zimmerman JJ, Harper DM, Matschke K, et al. Absence of an interaction between tigecycline and digoxin in healthy men. Pharmacotherapy 2007;27:835-844 (Pubitemid 46849427)
35. Raible DG, Zimmerman JJ, Harper DM, Speth JL. Pharmacokinetics and pharmacodynamics of tigecycline and warfarin coadministered to healthy subjects (abstract A-21). Presented at: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC American Society of Microbiology 2005 December 16-19, 2005
36. Homer-Vanniasinkam S. Treatment of intra-abdominal and skin and soft tissue infections: the role of the glycylcyclines. Int J Surg 2006;4:45-52
37. Mallick R, Sun S, Schell SR. Predictors of efficacy and health resource utilization in treatment of complicated intra-abdominal infections: evidence for pooled clinical studies comparing tigecycline with imipenem-cilastatin. Surg Infect (Larchmt) 2007;8:159-172 (Pubitemid 46626651)
38. Postier RG, Green SL, Klein SR, et al. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin Ther 2004;26:704-714 (Pubitemid 38736960)
39. Nord CE, Sillerstrom E, Wahlund E. Effect of tigecycline on normal oropharyngeal and intestinal microflora. Antimicrob Agents Chemother 2006;50:3375-3380 (Pubitemid 44527513)
40. Zhang YY, Zhou L, Zhu DM, et al. In vitro activities of tigecycline against clinical isolates from Shanghai, China. Diagn Microbial Infect Dis 2004;50:267-281
41. LaPlante KL, Rybak MJ, Leuthner KD, Chin JN. Impact of Enterococcus faecalis on the bactericidal activities of arbekacin, daptomycin, linezolid, and tigecycline against methicillin-resistant Staphylococcus aureus in a mixed-pathogen pharmacodynamic model. Antimicrob Agents Chemother 2006;50:1298-1303
42. Petersen PJ, Jones CH, Bradford PA. In vitro antibacterial activities of tigecycline and comparative agents by time-kill kinetic studies in fresh Mueller-Hinton broth. Diagn Microbiol Infect Dis 2007;59:347-349
43. Sader HS, Jones RN, Dowzicky MJ, Fritsche TR. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Diagn Microbiol Infect Dis 2005;52:203-208 (Pubitemid 41133546)
44. Townsend ML, Pound MW, Drew RH. Tigecycline: a new glycylcycline antimicrobial. Int J Clin Pract 2006;60:1662-1672 (Pubitemid 44742168)
45. Visalli MA, Murphy E, Projan SJ, Bradford PA. AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis. Antimicrob Agents Chemother 2003;47:665-669 (Pubitemid 36158098)
46. Dean CR, Visalli MA, Projan SJ, et al. Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1. Antimicrob Agents Chemother 2003;47:972-978 (Pubitemid 36254223)
47. Fraise AP. Tigecycline: the answer to beta-lactam and fluoroquinolone resistance? J Infect 2006;53:293-300
48. Wilcox MH. Tigecycline and the need for a new broad-spectrum antibiotic class. Surg Infect 2006;7:69-80 • Describes the minimal affect of tigecycline on the displacement of normal microbial flora.
49. Hawkey P, Finch R. Tigecycline: in-vitro performance as a predictor of clinical efficacy. Clin Microbiol Infect 2007;13:354-362 (Pubitemid 46390220)
50. Livermore DM. Tigecycline: what is it, and where should it be used? J Antimicrob Chemother 2005;56:611-614
51. Livermore DM. Introduction: the challenge of multiresistance. Int J Antimicrob Agents 2007;29(Suppl 3):S1-7 (Pubitemid 47058919)
52. Livermore DM, Woodford N. The beta-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. Trends Microbiol 2006;14:413-420
53. Pankey GA, Steele RW. Tigecycline: a single antibiotic for polymicrobial infections. Pediatr Infect Dis J 2007;26:77-78 (Pubitemid 46045757)
54. Scheinfeld N. Tigecycline: a review of a new glycylcycline antibiotic. J Dermatolog Treat 2005;16:207-212 (Pubitemid 41597532)
55. Scheinfeld N. A comparison of available and investigational antibiotics for complicated skin infections and treatment-resistant Staphylococcus aureus and enterococcus. J Drugs Dermatol 2007;6:97-103
56. Slover CM, Rodvold KA, Danziger LH. Tigecycline: a novel broad-spectrum antimicrobial. Ann Pharmacother 2007;41:965-972 (Pubitemid 46917623)
57. Bradford PA, Weaver-Sands DT, Petersen PJ. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Clin Infect Dis 2005;41(Suppl 5):S315-32
58. Reynolds R, Potz N, Colman M, et al. Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-2002: the BSAC Bacteraemia Resistance Surveillance Programme. J Antimicrob Chemother 2004;53:1018-1032
59. Hoban DJ, Bouchillon SK, Dowzicky MJ. Antimicrobial susceptibility of extended-spectrum beta-lactamase producers and multidrug-resistant Acinetobacter baumannii throughout the United States and comparative in vitro activity of tigecycline, a new glycylcycline antimicrobial. Diagn Microbiol Infect Dis 2007;57:423-428 (Pubitemid 46498663)
60. Hoban DJ, Bouchillon SK, Johnson BM, et al. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Diagn Microbiol Infect Dis 2005;52:215-227
61. Bouchillon SK, Hoban DJ, Johnson BM, et al. In vitro activity of tigecycline against 3989 gram-negative and gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004). Diagn Microbiol Infect Dis 2005;52:173-179
62. Bouchillon SK, Hoban DJ, Johnson BM, et al. In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002. Diagn Microbiol Infect Dis 2005;51:291-295
63. Reinert RR, Low DE, Rossi F, et al. Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline. J Antimicrob Chemother 2007;60:1018-1029 (Pubitemid 47617749)
64. Goldstein EJ, Citron DM, Merriam CV, et al. Comparative in vitro susceptibilities of 396 unusual anaerobic strains to tigecycline and eight other antimicrobial agents. Antimicrob Agents Chemother 2006;50:3507-3513 (Pubitemid 44527540)
65. Chopra I, Schofield C, Everett M, et al. Treatment of health-care-associated infections caused by gram-negative bacteria: a consensus statement. Lancet Infect Dis 2008;8:133-139
66. Maltezou HC. Metallo-beta-lactamases in gram-negative bacteria: introducing the era of pan-resistance? Int J Antimicrob Agents 2008 [Epub ahead of print]
67. Souli M, Kontopidou FV, Koratzanis E, et al. In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, gram-negative and gram-positive clinical isolates from Greek hospitals. Antimicrob Agents Chemother 2006;50:3166-3169
68. Cobo J, Morosini MI, Pintado V, et al. Use of tigecycline for the treatment of prolonged bacteremia due to a multiresistant VIM-1 and SHV-12 beta-lactamase-producing Klebsiella pneumoniae epidemic clone. Diagn Microbiol Infect Dis 2008;60:319-322 (Pubitemid 351255574)
69. Souli M, Kontopidou FV, Papadomichelakis E, et al. Clinical experience of serious infections caused by Enterobacteriaceae producing VIM-1 metallo-beta-lactamase in a Greek University Hospital. Clin Infect Dis 2008;46:847-854
70. DiPersio JR, Dowzicky MJ. Regional variations in multidrug resistance among Enterobacteriaceae in the USA and comparative activity of tigecycline, a new glycylcycline antimicrobial. Int J Antimicrob Agents 2007;29:518-527 (Pubitemid 46560368)
71. Tuckman M, Petersen PJ, Howe A, et al. Occurrence of Tetracycline Resistance Genes Among Escherichia coli Isolates from the Phase 3 Clinical Trials for Tigecycline. Antimicrob Agents Chemother 2007;51:3205-3211 (Pubitemid 350067529)
72. Vasilev K, Reshedko G, Orasan R, et al. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae. J Antimicrob Chemother 2008;62(Suppl 1):i29-40
73. Castanheira M, Sader HS, Deshpande LM, et al. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother 2008;52:570-573 (Pubitemid 351170830)
74. Sader HS, Jones RN, Stilwell MG, et al. Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents. Diagn Microbiol Infect Dis 2005;52:181-186 (Pubitemid 41133543)
75. Bratu S, Tolaney P, Karumudi U, et al. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J Antimicrob Chemother 2005;56:128-32 • Comprehensive assessment of the in vitro potency of tigecycline in various regions of the world.
76. Izdebski R, Sadowy E, Fiett J, et al. Clonal diversity and resistance mechanisms in tetracycline-nonsusceptible Streptococcus pneumoniae isolates in Poland. Antimicrob Agents Chemother 2007;51:1155-63 • Comprehensive assessment of the in vitro potency of tigecycline and comparator agents against anaerobic MDR Enterobacteriaceae.
77. Amyes SG. Enterococci and streptococci. Int J Antimicrob Agents 2007;29(Suppl 3):S43-52 (Pubitemid 47064504)
78. Vázquez MF, Romero ED, García MI, et al. Comparative in vitro activity of tigecycline against enterobacteria producing two or more extended-spectrum beta-lactamases. Int J Antimicrob Agents 2008;32:541-543
79. Naesens R, Ursi JP, Van Schaeren J, Jeurissen A. In vitro activity of tigecycline against multidrug-resistant Enterobacteriaceae isolates from a Belgian hospital. Eur J Clin Microbiol Infect Dis 2008 [Epub ahead of print]
80. Wybo I, Piérard D, Verschraegen I, et al. Third Belgian multicentre survey of antibiotic susceptibility of anaerobic bacteria. J Antimicrob Chemother 2007;59:132-139 (Pubitemid 46017916)
81. Daly MW, Riddle DJ, Ledeboer NA, et al. Tigecycline for treatment of pneumonia and empyema caused by carbapenemase-producing Klebsiella pneumoniae. Pharmacotherapy 2007;27:1052-1057 (Pubitemid 46986692)
82. Scheetz MH, Qi C, Warren JR, et al. In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2007;51:1621-1626
83. Halstead DC, Abid J, Dowzicky MJ. Antimicrobial susceptibility among Acinetobacter calcoaceticus-baumannii complex and Enterobacteriaceae collected as part of the Tigecycline Evaluation and Surveillance Trial. J Infect 2007;55:49-57 (Pubitemid 46900073)
84. Song JY, Kee SY, Hwang IS, et al. In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother 2007;60:317-322
85. Reid GE, Grim SA, Aldeza CA, et al. Rapid development of Acinetobacter baumannii resistance to tigecycline. Pharmacotherapy 2007;27:1198-1201 (Pubitemid 47173663)
86. Navon-Venezia S, Leavitt A, Carmeli Y. High tigecycline resistance in multidrug-resistant Acinetobacter baumannii-authors' response. J Antimicrob Chemother 2007;60:178-179 (Pubitemid 47073300)
87. Peleg AY, Adams J, Paterson DL. Tigecycline efflux as a mechanism for nonsusceptibility in Acinetobacter baumannii. Antimicrob Agents Chemother 2007;51:2065-9 • Comprehensive assessment of the in vitro potency of tigecycline against Acinetobacter and Enterobacteriaceae.
88. Navon-Venezia S, Leavitt A, Carmeli Y. High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother 2007;59:772-774 (Pubitemid 47078722)
89. Peleg AY, Potoski BA, Rea R, et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother 2007;59:128-131 (Pubitemid 46017915)
90. Thamlikitkul V, Tiengrim S, Tribuddharat C. Comment on: high tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother 2007;60:177-8; author reply 8-9 (Pubitemid 47073299)
91. Vancomycin Sterile; Generic Name: vancomycin hydrochloride; Dosage Form: injection, powder, lyophilized, for solution, 2007;. Available from: http://www.drugs. com/pro/vancomycin-sterile.html [Last accessed 16 October 2008]
92. Hidayat LK, Hsu DI, Quist R, et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006;166:2138-2144 (Pubitemid 44631403)
93. Wood MJ. Comparative safety of teicoplanin and vancomycin. J Chemother 2000;12(Suppl 5):21-25
94. Segarra-Newnham M, Tagoff SS. Probable vancomycin-induced neutropenia. Ann Pharmacother 2004;38:1855-1859 (Pubitemid 39425721)
95. Zeckel ML. A closer look at vancomycin, teicoplanin, and antimicrobial resistance. J Chemother 1997;9:311-31; discussion 32-35 (Pubitemid 27469642)
96. Selimoglu E. Aminoglycoside-induced ototoxicity. Curr Pharm Des 2007;13:119-126 (Pubitemid 46085303)
97. Drusano GL, Ambrose PG, Bhavnani SM, et al. Back to the future: using aminoglycosides again and how to dose them optimally. Clin Infect Dis 2007;45:753-760 (Pubitemid 47378891)
98. Paterson DL. Clinical experience with recently approved antibiotics. Curr Opin Pharmacol 2006;6:486-490 (Pubitemid 44348532)
99. Wilcox MH. Update on linezolid: the first oxazolidinone antibiotic. Expert Opin Pharmacother 2005;6:2315-2326 (Pubitemid 41582217)
100. CUBIST. Cubicin (daptomycin for injection) full prescribing information. 2007(October 2007) 1004-1007
101. Rybak MJ. The efficacy and safety of daptomycin: first in a new class of antibiotics for gram-positive bacteria. Clin Microbiol Infect 2006;12(Suppl 1):24-32
102. Guay DR. Daptomycin: the first approved lipopeptide antimicrobial. Consult Pharm 2004;19:614-628 (Pubitemid 38890900)
103. Reuther LO, Pedersen ST, Ronn AM. Drug-induced seizures. Ugeskr Laeger 2003;165:1447-1451 (Pubitemid 38094480)
104. Zhanel GG, Wiebe R, Dilay L, et al. Comparative review of the carbapenems. Drugs 2007;67:1027-1052 (Pubitemid 46744477)
105. Lin SW, Carver PL, DePestel DD. Dalbavancin: a new option for the treatment of gram-positive infections. Ann Pharmacother 2006;40:449-460
106. Linden P. Safety profile of meropenem: an updated review of over 6,000 patients treated with meropenem. Drug Saf 2007;30:657-668 (Pubitemid 47295825)
107. Edwards SJ, Emmas CE, Campbell HE. Systematic review comparing meropenem with imipenem plus cilastatin in the treatment of severe infections. Curr Med Res Opin 2005;21:785-794 (Pubitemid 40695301)
108. Schmitt-Hoffmann A, Roos B, Schleimer M, et al. Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob Agents Chemother 2004;48:2570-2575 (Pubitemid 38823426)
109. Chapman TM, Perry CM. Cefepime: a review of its use in the management of hospitalized patients with pneumonia. Am J Respir Med 2003;2:75-107 (Pubitemid 37062719)
110. Perry CM, Markham A. Piperacillin/ tazobactam: an updated review of its use in the treatment of bacterial infections. Drugs 1999;57:805-843 (Pubitemid 29231894)